DYN — Dyne Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.26bn
- $614.52m
- 31
- 23
- 12
- 10
Annual income statement for Dyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 58.6 | 150 | 171 | 242 | 344 |
| Operating Profit | -58.6 | -150 | -171 | -242 | -344 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -59.4 | -149 | -168 | -236 | -317 |
| Net Income After Taxes | -59.4 | -149 | -168 | -236 | -317 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -59.4 | -149 | -168 | -236 | -317 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -59.4 | -149 | -168 | -236 | -317 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.32 | -2.93 | -3.23 | -3.95 | -3.37 |